Regeneron Sues Sandoz to Block Just-Approved Biosimilar of Eylea

Regeneron Pharmaceuticals Inc. sued Sandoz Group AG seeking damages and an order blocking Enzeevu, a recently approved biosimilar version of its blockbuster eye drug Eylea that it said infringes 46 patents.

Sandoz Inc., a subsidiary based in Princeton, N.J., failed to provide information about its biosimilar as required by the Biologics Price Competition and Innovation Act, according to a complaint filed Monday in the US District Court for the District of New Jersey.

Regeneron said that kept it from evaluating whether Enzeevu infringes its patents for the macular degeneration treatment before the US Food and Drug Administration’s approval, which ...